GLP-1
Also called glucagon-like peptide-1, GLP-1 receptor agonist.
By Dr Chad Okay4 min read
GLP-1 stands for glucagon-like peptide-1. It is a hormone made in the lower part of the small intestine, released when food arrives. It tells the pancreas to release insulin, slows the stomach down so meals last longer, and signals the brain that you are full. Drugs like Ozempic, Wegovy and Mounjaro mimic this signal at much higher levels.
What the hormone does naturally
GLP-1 is one of the body's incretin hormones. It is released by L-cells in the lining of the lower small intestine within minutes of eating. Its three main jobs are to trigger insulin release in response to glucose, slow gastric emptying so the stomach holds food for longer, and reduce appetite by acting on receptors in the hypothalamus.
Natural GLP-1 has a half-life of about two minutes. The body breaks it down quickly using an enzyme called DPP-4. This is why eating-induced satiety fades within a couple of hours and people get hungry again.
How GLP-1 receptor agonist drugs work
GLP-1 receptor agonists, often called GLP-1RAs, are synthetic versions of the hormone designed to last much longer than the natural one. Most current drugs are once-weekly injections. They produce a sustained signal where the natural hormone gives a short pulse. The result is a much stronger and longer-lasting reduction in appetite, slower stomach emptying, and tighter blood-sugar control.
The drugs in this class
- Semaglutide: Ozempic (for type 2 diabetes), Wegovy (for weight management), Rybelsus (oral form for diabetes).
- Tirzepatide: Mounjaro (diabetes), Zepbound (weight management). Acts on both GLP-1 and GIP receptors, hence dual agonist.
- Liraglutide: Victoza (diabetes), Saxenda (weight management). Daily injection.
- Dulaglutide: Trulicity (diabetes only).
- Older or in-development: exenatide, lixisenatide, retatrutide (triple agonist, in trials), orforglipron (oral non-peptide, in late-stage trials).
Why these drugs cause gut symptoms
The same mechanism that makes GLP-1RAs effective for weight loss is what produces side effects. Slowed stomach emptying means food sits longer, so nausea and reflux are common in the first weeks. Slower movement carries through the rest of the gut as well, so constipation appears in roughly 1 in 5 to 1 in 4 users at higher doses (around 24% on Wegovy at 2.4 mg in the STEP trials, lower for tirzepatide and lower-dose semaglutide). Most symptoms settle within four to six weeks of reaching a stable dose, but flare again with each dose increase.
What GLP-1 is not
GLP-1 is not the same as insulin, even though it triggers insulin release. It is not a fat-burning drug. It works by reducing appetite and food intake, which produces a calorie deficit. Stopping the drug usually causes the appetite signal to return, and weight regain is common unless eating habits and lean muscle mass have been protected during treatment.
If something feels wrong
This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.
Common questions
GLP-1 is the natural hormone made in your gut. GLP-1 receptor agonists are the synthetic drugs that mimic it. People often use the term GLP-1 to mean both, but they are different things. The drugs last days; the hormone lasts minutes.
Sources
- 1Tirzepatide for managing overweight and obesity (TA1026), RecommendationsNICE
- 2Wilding et al. 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJMNew England Journal of Medicine (via PubMed)
- 3Jastreboff et al. 2022, Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJMNew England Journal of Medicine (via PubMed)
- 4Wilding et al. 2022, Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 1 trial extensionDiabetes, Obesity and Metabolism (via PMC)
- 5Wharton et al. 2022, Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesityDiabetes, Obesity and Metabolism (via PubMed)
- 6Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine (2017)Diabetes (American Diabetes Association, via PMC)
- 7Shah & Vella 2014, Effects of GLP-1 on appetite and weight (GLP-1 and appetite review)Reviews in Endocrine and Metabolic Disorders (via PMC)
- 8Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
Related terms




